Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Technology
Study Phase : Discovery Platform
Recipient : Lonza Group
Deal Size : Undisclosed
Deal Type : Collaboration
Lonza Collaborates with Cristal Therapeutics and McSAF to Expand Bioconjugates Offering
Details : The collaborations will enable the integration of McSAF Inside® and Cristal Therapeutic's CliCr®, into the Lonza Bioconjugation Toolbox and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates and antibody-drug con...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 17, 2023
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Recipient : Lonza Group
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery Platform
Sponsor : Intravacc
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, Cristal Therapeutics and Intravacc will collaborate with an initial focus on generating a CriVac® vaccine candidate based on the receptor-binding domain of the SARS-CoV-2 spike protein.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
January 06, 2021
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery Platform
Sponsor : Intravacc
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
